OTC Bulletin Board S & P Company Insight for HUIFENG BIO-PHARM TH
Profile
	Business Summary: Huifeng Bio-Pharmaceutical Technology Inc. produces and sells plant extracts, biochemical products and pharmaceutical raw products in the People's Republic of China. It produces a series of Rutin and Rutin-related products.   Address   16B/F Ruixin Road Bldg. No. 25 Gaoxin Road Xi An   Xian , Shaanxi Province 710075   Phone: 86-29-8822-4682 Auditor   JIMMY C.H. CHEUNG & CO. Transfer Agent   Interwest Transfer Co. Inc. Employees:  221 ShareHolders:  644 Founded:  2000 Domicile:  Nevada
Background
	Huifeng Bio-Pharmaceutical Technology Inc. produces and sells plant extracts, biochemical products and pharmaceutical raw products in the People's Republic of China. Huifeng believes it possesses one of the most advanced and patented Rutin-refining technologies in China, and it is a major Rutin supplier for the world market. Huifeng produces a series of Rutin and Rutin-related products, including pharmaceutical intermediates (NF11 Rutin, DAB8_DAB9_DAB10_DAB11 Rutin, Troxerutin, Quercetin, L-Rhamnone); pharmaceutical material (Venoruton, Rutin, Berberine Hydrochloride, Matrine, Diosmin, L-Rhamnose); and plant extracts (Hesperidin, Naringin, Epimedium Extract, Matrine, Puerorin, Siybun Marianum P.E). The chemical name of Rutin is rue glycoside and it is a kind of plant extract. It can inhibit platelet aggregation and prevent thrombosis. It can also improve the permeability of capillary vessels, and has the properties of: anti-inflammatory; decreasing blood pressure and fat; and mitigating cerebral hemorrhage. Additionally, it has a positive effect in protecting heart and cerebral hemorrhage and ischemia-reperfusion injury. It is widely used as a raw material for the heart and cerebral blood vessel medicines as well as an additive for cosmetics and functional food. According to the company, the demand for Rutin increases at an annual rate of approximately 30% due to the increased demand for heart and cerebral blood vessel medicines as a result of the aging population. Furthermore, the improvement in living standards in China also stimulates the growth in the demand for functional food and natural cosmetics. During 2006, the company finished two new products lines, Diosmin and L-Rhamnose. Huifeng has two major production facilities, a manufacturing plant located in Changwu, Xianyang and another plant located in Fenghui, Changan, Xian. The two production facilities together occupy a total area of approximately 300,000 square feet. The company maintains its headquarters in Xian, Shaanxi Province, People's Republic of China. History:  INCORPORATED in Nevada Mar. 16, 2000, as EnterNet, Inc. Name changed to Secured Data Inc. June 7, 2002; and to Huifeng Bio-Pharmaceutical Technology Inc. Oct. 12, 2005.   Subsidiaries: Northwest Bio-Technic Inc. Shaanxi Huifeng Pharmaceutical Company Limited Xi'an Huifeng Biochemistry Engineering Company Limited Xian Huifeng Biochemistry Group Joint-Stock Company Limited     Capital Expenditures, thousand. US Dollars   Year   Amount   2008   2,648   2007   331   2006   159   Research and Development Expenditures, thousand. US Dollars   Year   Amount   2008   24   2007   26
Management
	Management Officers Position  Jingan  Wang Chairman & Chief Executive Officer  Sanding  Tao Chief Financial Officer  Xinwen  Hou Secretary Directors  Xinwen  Hou  Sanding  Tao  Jingan  Wang
Annual Report
	Annual Report   Income Statement   2008 2007 NET SALES $10,957,229 $6,571,531 COST OF SALES (7,136,492) (4,594,218) GROSS PROFIT 3,820,737 1,977,313 OPERATING EXPENSES Selling expenses and distribution expenses 209,131 105,347 General and administrative expenses 1,157,196 349,591 Depreciation and amortization 49,000 47,951 Total Operating Expenses 1,415,327 502,889 INCOME (LOSS) FROM OPERATIONS 2,405,410 1,474,424 Interest income 16,824 23,520 Interest expenses (590,602) (30,463) Other income 264,004 109,797 Other expenses -- (48,307) INCOME TAX EXPENSE (528,570) (265,972) MINORITY INTEREST (14,635) 20,684 NET INCOME 1,552,431 1,283,683 Net income per share-basic $0.08 $0.07 Net income per share-diluted $0.08 $0.07   Balance Sheet   2008 2007 ASSETS CURRENT ASSETS Cash and cash equivalents $45,474 $2,219,694 Accounts receivable, net of allowances 2,877,868 1,660,829 Inventories, net 4,740,230 2,657,305 Other assets 328,996 1,011,985 Total Current Assets 7,992,668 7,549,813 PROPERTY AND EQUIPMENT, NET 5,947,458 3,509,344 LAND USE RIGHTS, NET 148,564 142,334 TOTAL ASSETS $14,088,690 $11,201,491 LIABILITIES AND STOCKHOLDERS' EQUITY CURRENT LIABILITIES Convertible notes payable 1,676,907 -- Accounts payable $520,280 $93,126 Other payables and accrued expenses 407,726 245,568 Income tax and other tax payables 538,483 498,655 Notes payable 281,579 295,320 Due to stockholders -- 280,503 Total Current Liabilities 3,424,975 1,413,172 Convertible notes payable -- 1,353,814 MINORITY INTEREST 507,679 461,826 STOCKHOLDERS' EQUITY Common stock, $0.018 par value 332,388 332,388 Additional paid-in capital 8,355,863 8,326,752 Retained earnings (deficit) Unappropriated (403,795) (1,671,410) Appropriated 504,780 219,964 Accumulated other comprehensive income 1,366,800 764,985 Total Stockholders' Equity 10,156,036 7,972,679 TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY $14,088,690 $11,201,491
Interim Report
	Interim Report      Data Not Available
Pro Forma Report
	Pro Forma Report      Data Not Available
Quarterly Report
	Quarterly Report Information      Quarterly Revenue, US$ Year Quarter Revenue   2009   1 1,330,000   2008   1 2,590,000   2008   2 2,760,000   2008   3 3,530,000   2008   Full Year 10,960,000   2007   1 1,400,000   2007   2 1,610,000   2007   Full Year 6,570,000   2006   1 1,100,000   2006   2 460,000   2006   3 820,000   2006   Full Year 3,080,000   2005   1 930,000   2005   2 420,000   2005   3 640,000   2005   Full Year 2,440,000   2004   1 Nil   2004   2 Nil   2004   3 Nil   2004   Full Year 2,480,000     Quarterly Net Income, US$ Year Quarter Revenue   2009   1 (390,000)   2008   1 340,000   2008   2 360,000   2008   3 770,000   2007   1 310,000   2007   2 390,000   2007   3 (20,000)   2006   1 130,000   2006   2 (50,000)   2006   3 80,000   2005   1 50,000   2005   2 50,000   2005   3 10,000   2005   Full Year (832,800)   2004   1 (90,000)   2004   2 (400,000)   2004   3 (20,000)   2004   Full Year (718,400)     Quarterly EPS, US$ Year Quarter Revenue   2009   1 (.02)   2008   1 .02   2008   2 .02   2008   3 .04   2008   Full Year .08   2007   1 .02   2007   2 .02   2007   3 Nil   2007   Full Year .07   2006   1 .01   2006   2 Nil   2006   3 .01   2006   Full Year .01   2005   1 Nil   2005   2 Nil   2005   3 Nil   2005   Full Year (.11)   2004   1 (.18)   2004   2 (.72)   2004   3 Nil   2004   Full Year (.18)
Stock Data
	Capitalization as of 03/31/2009:     Authorized Shares Outstanding Shares Common $0.018 par 100,000,000 18,466,169 Preferred $0.001 par 5,000,000 None   LONG TERM DEBT: $1,757,680.   Common $0.018 par   COMMON OFFERED: December 14, 2000, the company offered 10,000,000 Common shares at $0.01 per share on a continuous basis, with no minimum purchase requirement. The offering was not underwritten. All shares were sold in January 2001.   Stockholders:  03/11/2009, 644. PRINCIPAL STOCKHOLDERS: March 11, 2009, Jingan Wang owned or controlled 39.6% of the Common.   Transfer Agent:  Interwest Transfer Co. Inc.   Salt Lake City , UT   OTC Bulletin Board( Primary): HFGB   Exchange Year High Low OTC Bulletin Board 2009 1.2900 0.1500 OTC Bulletin Board 2008 1.4500 0.2600 OTC Bulletin Board 2007 1.0100 0.2700 OTC Bulletin Board 2006 0.7500 0.2100 OTC Bulletin Board 2005 2.1500 0.2500 OTC Bulletin Board 2004 2.0000 0.0200 OTC Bulletin Board 2003 0.7050 0.0900 OTC Bulletin Board 2002 0.3000 0.0100 OTC Bulletin Board 2001 3.2500 0.8000   DIVIDENDS: Common $0.018 par: No cash. Common split 6-for-5, June 7, 2002. Common reverse split 1-for-15, Jan. 12, 2004. Common reverse split 1-for-18, Oct. 12, 2005.